ProQR Therapeutics (NASDAQ:PRQR) Upgraded at StockNews.com

StockNews.com upgraded shares of ProQR Therapeutics (NASDAQ:PRQRFree Report) from a sell rating to a hold rating in a report released on Saturday.

Several other brokerages also recently commented on PRQR. Chardan Capital reissued a buy rating and issued a $2.50 price target on shares of ProQR Therapeutics in a report on Friday, May 10th. HC Wainwright reissued a buy rating and issued a $5.00 price target on shares of ProQR Therapeutics in a report on Friday, May 10th. Finally, Citigroup raised their price target on shares of ProQR Therapeutics from $1.80 to $2.00 and gave the company a buy rating in a report on Thursday, April 18th. One investment analyst has rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, ProQR Therapeutics currently has an average rating of Moderate Buy and a consensus target price of $3.38.

Get Our Latest Analysis on ProQR Therapeutics

ProQR Therapeutics Trading Down 1.0 %

PRQR opened at $1.92 on Friday. The company has a 50 day moving average of $2.13 and a 200 day moving average of $1.98. The company has a market cap of $156.20 million, a PE ratio of -5.19 and a beta of 0.30. ProQR Therapeutics has a 12 month low of $1.11 and a 12 month high of $3.29.

ProQR Therapeutics (NASDAQ:PRQRGet Free Report) last released its quarterly earnings data on Wednesday, March 13th. The biopharmaceutical company reported ($0.08) EPS for the quarter, hitting the consensus estimate of ($0.08). The company had revenue of $3.54 million during the quarter, compared to the consensus estimate of $27.88 million. ProQR Therapeutics had a negative net margin of 260.75% and a negative return on equity of 61.58%. Research analysts forecast that ProQR Therapeutics will post -0.37 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of PRQR. EP Wealth Advisors LLC purchased a new stake in shares of ProQR Therapeutics during the 1st quarter valued at $26,000. Acadian Asset Management LLC purchased a new stake in shares of ProQR Therapeutics during the 1st quarter valued at $56,000. RFG Advisory LLC purchased a new stake in shares of ProQR Therapeutics during the 1st quarter valued at $73,000. BNP Paribas Financial Markets raised its position in shares of ProQR Therapeutics by 120.1% during the 1st quarter. BNP Paribas Financial Markets now owns 35,001 shares of the biopharmaceutical company’s stock valued at $80,000 after buying an additional 19,100 shares in the last quarter. Finally, Monaco Asset Management SAM raised its position in shares of ProQR Therapeutics by 58.9% during the 3rd quarter. Monaco Asset Management SAM now owns 377,517 shares of the biopharmaceutical company’s stock valued at $491,000 after buying an additional 140,000 shares in the last quarter. 32.65% of the stock is owned by institutional investors.

ProQR Therapeutics Company Profile

(Get Free Report)

ProQR Therapeutics N.V., a biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company's products pipeline includes AX-0810 for cholestatic diseases targeting Na-taurocholate cotransporting polypeptide (NTCP); and AX-1412 for cardiovascular diseases (CVDs) targeting Beta-1,4-galactosyltransferase 1 (B4GALT1).

Featured Articles

Receive News & Ratings for ProQR Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProQR Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.